HIV drug nevirapine (Viramune): risk of severe hepatotoxicity

被引：6
|
作者：
Wooltorton, E
机构：
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2004年 / 170卷 / 07期
关键词：
D O I：
10.1503/cmaj.1040417
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1091 / 1091
页数：1
相关论文
共 50 条
  • [1] Nevirapine -: Viramune® -: Anti-HIV -: Reverse transcriptase inhibitor
    不详
    DRUGS OF THE FUTURE, 2000, 25 (10) : 1098 - 1098
  • [2] Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine
    Shahar, E
    Krivoy, N
    Weltfriend, S
    Pollack, S
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2004, 57 (05) : 212 - 213
  • [3] Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects
    Sanne, I
    Mommeja-Marin, H
    Hinkle, J
    Bartlett, JA
    Lederman, MM
    Maartens, G
    Wakeford, C
    Shaw, A
    Quinn, J
    Gish, RG
    Rousseau, F
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (06): : 825 - 829
  • [4] Incidence of and risk factors for hepatotoxicity associated with nevirapine in HIV-1 infected patients
    Launay, O
    Boukli, N
    Tréluyer, JM
    Roudiere, L
    Rey, E
    Urbinelli, R
    Allaert, FA
    Caumes, E
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 : S121 - S121
  • [5] Safety-related changes to the nevirapine (Viramune®) label
    Mallolas, J
    AIDS REVIEWS, 2005, 7 (03) : 182 - 183
  • [6] Risk of liver toxicity in HIV/HCV coinfected patients with advanced chronic liver disease receiving nevirapine (Viramune®) or lopinavir/ritonavir (Kaletra®)
    Dragovic, G.
    Jevtovic, D. J.
    DRUG SAFETY, 2006, 29 (10) : 985 - 985
  • [7] US FDA informs public of Viramune hepatotoxicity
    Reactions Weekly, 2005, 1036 (1) : 2 - 2
  • [8] New hepatotoxicity information added to US Viramune label
    Reactions Weekly, 2004, 987 (1) : 3 - 3
  • [9] The Viramune® (nevirapine) hepatic safety project:: analysis of symptomatic hepatic events
    Imperiale, SM
    Lanes, SF
    Stern, JO
    Love, JT
    Robinson, PA
    Mayers, DL
    ANTIVIRAL THERAPY, 2002, 7 (03) : L57 - L58
  • [10] Risk of hepatotoxicity in virologically suppressed HIV patients switching to nevirapine according to gender and CD4 count
    De Lazzari, E.
    Leon, A.
    Arnaiz, J. A.
    Martinez, E.
    Mallolas, J. M.
    Blanco, J. L.
    Laguno, M.
    Larrousse, M.
    Milinkovic, A.
    Lonca, M.
    Gatell, J. M.
    ANTIVIRAL THERAPY, 2006, 11 (07) : L8 - L8
12345